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Abstract
Background: In HIV-infected patients receiving rifampicin-based treatment for tuberculosis (TB), the dosage of lopinavir/
ritonavir (LPV/r) is adjusted to prevent sub-therapeutic lopinavir concentrations. In this setting, South African clinicians were
advised to administer super-boosted LPV/r (400 mg/400 mg) twice daily, instead of standard dosed LPV/r (400 mg/100 mg)
twice daily. We sought to determine – in routine practice – the tolerability and HIV treatment outcomes associated with
super-boosted LPV/r compared to unadjusted LPV/r in combination with rifampicin-based TB treatment.
Methodology/Principle Findings: We conducted a retrospective review of HIV-infected patients who receiving second-line
ART with a LPV/r-containing regimen who required concomitant TB treatment. We identified 29 patients; the median age
was 36 years (IQR 29–40), 22 (76%) were female, the median CD4 cell count and viral load at first-line ART failure was
86 cells/mm3 (IQR 21–159) and 39,457 copies/mL (IQR 6,025–157,500), respectively. According to physician preference, 15
(52%) of 29 patients received super-boosted LPV/r (400 mg/400 mg) every 12 hours during TB treatment and 14 (48%) of 29
patients received standard dose LPV/r (400 mg/100 mg) twice daily during TB treatment. Among patients who received
super-boosted LPV/r there was a trend towards a higher rate of symptomatic transaminitis (27% vs. 7%; p = 0.3),
gastrointestinal toxicity (20% vs. 0%; p = 0.2) and a significantly increased need for treatment discontinuation (47% vs. 7%;
p = 0.035. The durability of coadministered treatment was significantly shorter in patients who received super-boosted
lopinavir/ritonavir with TB treatment compared to patients who received standard lopinavir/ritonavir dosing (log rank,
P= 0.036). The rate of virologic failure was not higher in patients with unadjusted LPV/r dosing.
Conclusions/Significance: We observed a high rate of toxicity and need for treatment discontinuation among patients on
standard rifampicin-based TB treatment who received super-boosted LPV/r.
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Introduction
A significant proportion of HIV-infected patients in South
Africa require second-line ritonavir-boosted protease inhibitor
(PI)-based antiretroviral therapy (ART) as a result of virologic
failure or intolerance of initial ART [1]. According to WHO
estimates, more than 100,000 patients have initiated second-line
ART, most commonly with a lopinavir/ritonavir (LPV/r)-
containing regimen [2]. However the management of tuberculosis
(TB) coinfection in such patients is challenging because rifampicin
– the cornerstone of antituberculous therapy – leads to a
substantial reduction in PI concentrations through the induction
of cytochrome p450 enzymes [3,4]. When administered with
rifampicin, reductions of greater than 90% in PI trough
concentrations have been observed [5,6].
The reduction in PI concentrations associated with concomitant
rifampicin can be attenuated with the use of higher doses of
ritonavir [3]. As a result, among patients receiving TB treatment,
clinicians in South Africa were advised to administer super-
boosted LPV/r (400 mg/400 mg) twice daily, instead of standard
dosed LPV/r (400 mg/100 mg) twice daily [7]. However, in a
previous study of healthy volunteers, super-boosted LPV/r was
associated with a high rate of nausea, vomiting and transaminase
elevations, resulting in early study termination [8]. Poor regimen
tolerability was also seen when adult patients with HIV and TB
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were treated with super-boosted LPV/r and rifampicin in the
Netherlands, with suboptimal antiviral efficacy observed in
coinfected patients who received standard LPV/r dosing [9].
Although widely used, there is very limited data from routine
clinical settings in low and middle-income countries on the
tolerability and antiviral efficacy of super-boosted lopinavir in
HIV-infected adult patients receiving rifampicin for TB infection.
We hypothesized that coinfected patients who received super-
boosted lopinavir (400 mg twice daily) would experience a
significantly higher rate of adverse events and tolerate a shorter
duration of concomitant TB treatment compared to patients
receiving standard lopinavir dosing.
Methods
McCord Hospital, a state-aided hospital, provides treatment for
HIV and tuberculosis to patients living in Durban and the
province of KwaZulu-Natal. We conducted a retrospective review
of HIV-infected patients who initiated second-line ART contain-
ing LPV/r at McCord Hospital between July 2004 and February
2007. Eligible for inclusion in the current study were adult patients
who received both LPV/r-containing second-line ART and
rifampicin for tuberculosis treatment for at least three months,
and who underwent a viral load test during the overlap period.
There was considerably clinician-to clinician variability regarding
the decision to use – during treatment of tuberculosis in patients
receiving LPV/r-based second-line ART – either super-boosted
LPV/r (400 mg/400 mg) twice daily or standard boosted LPV/r
(400 mg/100 mg) twice daily. In all instances, the dose of the
lopinavir component was 400 mg twice daily and the nucleoside
analogue dosing was standard. We excluded women who received
LPV/r-containing ART only as part of a prevention of a
maternal-to-child-transmission protocol.
Rifampicin was administered as part of a 4-drug (rifampicin,
isoniazid, pyrazinamide, ethambutol) fixed-dose combination
(FDC) or as a 2-drug (rifampicin and isoniazid) FDC, depending
upon whether the patient was receiving intensive phase or
continuation phase TB treatment. The second-line ART agents
available during the study included lopinavir/ritonavir [LPV/r
400/100 mg; available during the study period as soft-gel
formulation (Kaletra)]; ritonavir, lamivudine, didanosine (enteric-
coated formulation); zidovudine; and stavudine.
Patient monitoring followed South African Department of
Health recommendations including HIV-1 RNA level (detection
limit of ,50 copies/ml) and CD4 cell count monitoring every 6
months. Liver function testing was not obtained routinely during
coadministration of LPV/r and rifampicin-containing TB treat-
ment but was available to clinic staff in the presence of symptoms
or signs of hepatitis (defined as unexplained anorexia, nausea, right
upper quadrant pain or the presence of clinical jaundice). Adverse
events and abnormal laboratory results during coadministration
were graded according to the Division of AIDS Regulatory
Support Center guidance (7).
Using a standardized instrument, we abstracted from the patient
medical record clinical and demographic characteristics including
HIV-1 RNA levels, CD4 cell count, tuberculosis treatment history
and outcomes, adverse events detected by clinician and treatment
modification.
We compared baseline characteristics (at the time of first-line
ART failure), rates of key adverse events, treatment discontinu-
ation and virologic suppression among patients receiving second-
line ART and concomitant tuberculosis therapy who received
super-boosted lopinavir (400 mg twice daily) and patients who
received standard boosted lopinavir (100 mg twice daily). Cate-
gorical variables were compared using chi-square and Fisher’s
exact tests, and continuous variables were compared using
Student’s t-test. We defined the event treatment discontinuation
as the need to stop either rifampicin-based TB therapy or LPV/r-
based ART prematurely resulting from toxicity. We compared
event-free survival between patients who received super-boosted
lopinavir and patients who received standard boosted lopinavir, by
the Kaplan-Meier method.
Analyses were performed using SPSS software, version 18.0. All
tests of significance were two-sided; associations with P,0.05 were
considered significant.
The study was approved by the Research Ethics Committee at
McCord Hospital in Durban, South Africa. The Committee
waived the requirement for informed consent for this retrospective
data analysis.
Results
A total of 3025 patients initiated first-line ART at the
Sinikithemba clinic at McCord Hospital between July 2004 and
February 2007 and over that period 189 (6%) subsequently
required second-line LPV/r-containing ART as a result of
virologic failure or an adverse effect to initial ART. During that
period, we identified 29 patients who received concomitant
rifampicin and LPV/r-containing ART, representing 15% of
patients who initiated second-line ART. The median age for this
subgroup was 36 years (IQR 29–40), 22 patients (76%) were
female, the median CD4 cell count and viral load at first-line ART
failure was 86 cells/ml (IQR 21–159) and 39,457 copies/mL (IQR
6,025–157,500), respectively. The most common nucleosides used
with LPV/r in second-line ART were: AZT + DDI, 11 patients
(38%); D4T +3TC, 8 patients (28%); AZT +3TC, 7 patients
(24%); 3TC alone, 3 patients (10%).
Lopinavir was super-boosted (LPV/r 400 mg/400 mg twice
daily) in 15 (52%) of 29 patients and LPV/r dosing was standard
in 14 (48%) of 29 patients (LPV/r 400 mg/100 mg twice daily).
We compared the baseline characteristics of patients who received,
during tuberculosis therapy, super-boosted LPV/r and the
standard dose of LPV/r (Table 1). Among patients receiving
super-boosted LPV/r group 93% (14/15) were female and in the
standard LPV/r group, 57% (8/14) were female (P=0.03). There
were no other significant differences in the baseline characteristics
of the two groups at the time of first-line ART failure with respect
to age, CD4 cell count, viral load, weight, and second-line
nucleoside backbone.
Among patients who received coadministered rifampicin-
containing TB therapy and LPV/r -based ART, adverse reactions
were common. Hepatitis and gastrointestinal toxicity were the
most prominent adverse reactions (Figure 1). Overall, ALT
elevation of any grade was noted in 5 of 29 (17%) patients; there
were no grade 4 ALT elevations or deaths. Patients who received
super-boosted ritonavir experienced a trend towards a higher
overall rate of symptomatic transaminitis (27% vs. 7%; P=0.3)
and gastrointestinal toxicity (20% vs. 0%; P=0.2).
Overall, the mean period of coadministration of rifampicin-
containing TB therapy and LPV/r-based ART was 6.7 months
[range 1–11 months]. Months of coadminstered TB and LPV/r-
based ART treatment completed was evaluated as a function of
lopinavir/ritonavir dosing strategy utilizing a Kaplan-Meir anal-
ysis. Patients who received the super-boosted lopinavir/ritonavir
strategy had a significantly fewer months of dual therapy
completed prior to treatment discontinuation compared who
received standard lopinavir/ritonavir dosing (log rank, P=0.036;
Fig. 2). Also, the proportion of patients requiring discontinuation
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of treatment as a result of an adverse drug reaction was compared
between the super-boosted LPV/r and unadjusted-dose groups.
Patients who received super-boosted LPV/r were more likely to
require treatment discontinuation because of an adverse effect
(super-boosted LPV/r, 7 of 15 patients (47%); standard LPV/r, 1
of 14 patients (7%); P=0.035). The most common reason for
treatment discontinuation was transaminitis in the presence of
clinical symptoms or signs of hepatitis.
To explore if D4T or DDI may have been implicated in higher
rates of toxicity among patients receiving co-administered LPV/r
and rifampicin-containing TB treatment, we explored the
relationship between receiving a nucleoside backbone containing
DDI or D4T compared to a backbone without DDI or D4T on
rate of symptomatic transaminitis, gastrointestinal toxicity, and
rate of treatment discontinuation. There was no significant impact
of use of DDI or D4T-containing backbone on rate of
symptomatic transaminitis (P=0.775) or rate of gastrointestinal
toxicity (P=0.965). A Kaplan-Meir analysis revealed no relation-
ship between use of DDI or D4T in the backbone and treatment
discontinuation (log-rank, P=0.606).
We evaluated the proportion of patients in the two ritonavir
dose groups in whom virologic failure (HIV-1 RNA .200 c/mL)
was observed (Table 2). Overall, virologic failure during
coadministration was detected among 7 (24%) of 29 patients.
Among 15 patients who received super-boosted ritonavir, 3 (20%)
patients experienced virologic failure and among 14 patients who
received standard LPV/r, 4 (29%) experienced failure (P=0.7).
Table 1. Baseline characteristics of patients at initiation of lopinavir/ritonavir-based second line ART, according to treatment
group.
Characteristic
Lopinavir/ritonavir (400/400 mg)
twice daily (n=15)
Lopinavir/ritonavir (400/100 mg)
twice daily (n =14) P value
Age – yr
Mean 34.2 37.3 0.45
Range 21–64 11–59
Female sex – no. (%) 14 (93) 8 (57) 0.03
Weight – kg
Mean 61.1 54.9 0.26
CD4 cell count at first-line ART failure (cells/ul)
Median 92 70 0.78
Range 5–203 5–98
HIV-1 viral load at first-line ART failure (copies/mL)
Median 33,039 44,926 0.49
Second-line ART nucleoside backbone – no. (%)
DDI + AZT 6 (40) 5 (36)
AZT + 3TC 5 (33) 2 (14)
D4T + 3TC 4 (27) 4 (29)
Other 0 3 (21) 0.22
doi:10.1371/journal.pone.0044793.t001
Figure 1. Adverse events among patients who received standard dose and ‘‘super-boosted’’ lopinavir/ritonavir dosing during
concomitant treatment for tuberculosis.
doi:10.1371/journal.pone.0044793.g001
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Discussion
In South Africa, where the prevalence of HIV and tuberculosis
are among the highest in the world, we found that, overall, during
second-line ART with a LPV/r-containing regimen approximate-
ly 15% of patients required coadministration of rifampicin for
tuberculosis therapy. In our sample, co-infected patients who
received super-boosted LPV/r experienced a trend towards a
higher rate of symptomatic transaminitis, gastrointestinal toxicity
and the durability of coadministered treatment was significantly
Figure 2. Kaplan-Meier survival curve for the impact of lopinavir/ritonavir dosing strategy among patients with HIV/TB coinfection
on time until treatment discontinuation.
doi:10.1371/journal.pone.0044793.g002
Table 2. Clinical outcomes associated with coadministration of lopinavir/ritonavir-based ART and rifampicin-containing TB
treatment.
Outcome
Lopinavir/ritonavir (400/400 mg)
twice daily
Lopinavir/ritonavir (400/100 mg)
twice daily
N= 15 N= 14
HIV outcomes
Virologic failure (.200 c/mL), number (%) 3 (20) 4 (29)
Tuberculosis treatment outcomes
Months of overlapping therapy completed (mean) 5.4 8.1 *
Completed 12 (80) 13 (93)
Died or lost to follow-up 3 (20) 1 (7)
T-test, Chi-square, and Fisher’s tests used for comparisons, * p,0.05.
doi:10.1371/journal.pone.0044793.t002
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shorter resulting from adverse event-related treatment discontin-
uation (log rank test, P= 0.036). The most common reason for
treatment discontinuation was transaminitis in the presence of
clinical symptoms or signs of hepatitis. Early discontinuation of
coadministered lopinavir/ritonavir and rifampicin-based TB
treatment placed patients at risk for suboptimal treatment
outcomes. As the number of patients requiring boosted protease
inhibitor-containing therapy for HIV expands, the need for a
more varied drug formulary – to respond to common situations
such as TB co-infection – grows even more pressing.
Our findings confirmed concerns raised in prior studies about
concomitant use of rifampicin with superboosted LPV/r (400 mg/
400 mg twice daily) to prevent a reduction in lopinavir plasma
concentrations [8,9]. Currently the use of super-boosting LPV/r as
a strategy to overcome the effect of rifampicin on serum lopinavir
concentrations in adults is not recommended by the CDC [4].
However our findings contrast with a larger study by Frehoff and
colleagues who found – in South African children with HIV and
TB coinfection – that super-boosted LPV/r was generally well-
tolerated [10]. In the absence of similiar studies in adults, the
applicability of the pediatric data to adults with HIV and
tuberculosis coinfection is not clear.
We did not find a high rate of virologic failure associated with
coadministration LPV/r-based ART and TB treatment, either
among patients who received super-boosted LPV/r or standard
dose LPV/r, despite the known effect of rifampicin on reducing
lopinavir concentrations. However because of our relatively low
sample size, we cannot exclude such an effect. It should also be
considered that in the current study, patients were not homoge-
nous with respect to time since initiation of second-line ART.
Further, it has been previously reported that patients receiving
long-term boosted-protease inhibitor-containing ART may toler-
ate more variation in lopinavir concentrations without loss of
virologic control [11].
There are several limitations of this study. First, with regard to
the adverse events, we implicated specific drugs (ritonavir and
rifampicin) but cannot exclude a role for other drugs including the
NRTIs and other anti-tuberculosis drugs in the standard TB
treatment regimen including isoniazid. Second, patients who
received less than three months of coadministered LPV/r-
containing second-line ART and rifampicin-based TB treatment
were not included, potentially excluding patients who experienced
early adverse events. Third, adverse events were detected passively
during coadministration and therefore we are likely to have
underestimated the rate of these events. For example, a symptom-
based monitoring approach was used to monitor for hepatic
toxicity (transaminase levels were measured when symptoms or
signs resulted in concern for drug-induced hepatitis), and therefore
we were unable to detect subclinical elevations in transaminases. It
is possible that the a more intensive lab monitoring strategy would
have resulted in more adverse effects detected, but the relevance of
subclinical laboratory abnormalities is not clear [12].
Managing the competing risks of coadministered LPV/r-based
ART and rifampicin-containing TB treatment is complex, requires
access to laboratory services and – with the increasing use of
second-line ART – is likely to become a more common problem
over time. In the absence of additional drug options, efforts to use
existing agents to overcome the interaction between lopinavir and
rifampicin have continued. An additional potential dosing strategy
was illustrated by a recent small trial involving 18 co-infected
patients in South Africa. Decloedt and colleagues used double-
dose lopinavir/ritonavir in combination with rifampicin-based TB
treatment and found no grade 3 or 4 level toxicity and no evidence
of virologic breakthrough [13]. However most evidence suggests
that strategies involving increasing the ritonavir dose in adult
patients receiving LPV/r is associated with a relatively high rate of
adverse events and need for treatment discontinuation. It does not
appear to be an optimal long-term solution particularly in the
setting of efforts to reduce the need for lab monitoring and the shift
management of HIV-infected patients on long-term ART to less
trained medical cadres.
The replacement of rifampicin with rifabutin, in patients
receiving boosted PIs requiring TB treatment, is recommended
in high-income countries. Rifabutin can be substituted for
rifampicin in the treatment of TB without loss of efficacy and
rifabutin – when given at an adjusted dose of 150 mg every other
day – does not substantially lower lopinavir concentrations [14].
However, rifabutin concentrations may not be optimal when given
at this adjusted dose, the cost of rifabutin is relatively high and the
agent is not widely available in low and middle-income countries
[15]. Further rifabutin is not produced in a fixed-dose combina-
tion (FDC) making it poorly compatible with TB control
programmes which depend upon FDCs rather than individual
agents.
More feasible than the wider introduction of rifabutin may be
improving access to additional antiretroviral options in resource-
poor settings with potentially fewer important interactions with
rifampicin-based TB treatment. Raltegravir, an integrase inhibitor
which does not require boosting, can be dose-adjusted during
rifampicin-based TB treatment, is one promising alternative [16].
However raltegravir is not available as a generic and at current
pricing is inaccessible for most countries with generalized HIV
epidemics. Support for clinical trials in HIV and TB co-infected
patients in resource-limited settings will be critical to determine
regiment that will provide effective TB treatment, maintain high
levels of virologic suppression and do so with minimal side effects.
Until additional therapeutic options are made available in areas
with high burdens of HIV and TB – such as South Africa –
clinicians will be forced to manage HIV and TB coinfected
patients receiving LPV/r-based ART with treatment options that
may not be optimal.
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